- MLKL INHIBITORS
-
Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.
- -
-
Paragraph 0267-0268
(2018/09/26)
-
- Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
-
Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.
- -
-
Paragraph 0128
(2013/05/22)
-
